Cancer and Metastasis Reviews

Papers
(The median citation count of Cancer and Metastasis Reviews is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer252
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions129
Regulation of dormancy during tumor dissemination: the role of the ECM115
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities106
The functions and modifications of tRNA-derived small RNAs in cancer biology82
Clonal tracking in cancer and metastasis82
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression79
Obesity and cancer73
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective61
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms58
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?54
CAR T-cell therapy to treat multiple myeloma: current state and future directions53
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations53
Targeting lipid metabolism in cancer: neuroblastoma52
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor51
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer50
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond47
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review44
p73 isoforms meet evolution of metastasis42
Cell-cell interactions mediating primary and metastatic breast cancer dormancy41
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?40
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives39
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients38
Biography—Mathieu Boissan, Pharm.D., Ph.D37
Preface36
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance33
Neuropeptide Y in cancer—biological functions and potential clinical implications32
Biographies32
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications31
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance30
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis29
The role of cancer cell bioenergetics in dormancy and drug resistance29
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy28
Clusterin: a marker and mediator of chemoresistance in colorectal cancer28
Short-chain fatty acids in cancer pathogenesis28
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development27
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy27
Clinical interventions to break the obesity and cancer link: a narrative review26
Vaping and tumor metastasis: current insights and progress26
Carcinoma of unknown primary (CUP): an update for histopathologists26
Functional and clinical roles of stromal PDGF receptors in tumor biology26
Tumor necrosis factor superfamily signaling: life and death in cancer26
The emerging roles of histone demethylases in cancers26
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions26
Kenneth V. Honn, Ph.D. (1946–2023)25
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy25
OX40/OX40 ligand and its role in precision immune oncology25
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape25
Inflammatory bowel disease and carcinogenesis25
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy25
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution25
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review25
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective24
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies23
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect23
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases23
HOXA9 transcription factor is a double-edged sword: from development to cancer progression23
New progress of tuberculosis scar carcinoma22
Biographies22
Ferroptosis: iron release mechanisms in the bioenergetic process22
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases21
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX21
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs20
Is cancer an intelligent species?20
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment20
Metastasis suppressor genes in clinical practice: are they druggable?19
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics19
Oncobiology and treatment of breast cancer in young women18
Metastasis suppressor genes and their role in the tumor microenvironment18
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets18
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets18
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer17
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy17
The diversity of natural killer cell functional and phenotypic states in cancer17
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer17
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers17
De- “bug”-ing the microbiome in lung cancer16
Glycosylation as a regulator of site-specific metastasis16
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma16
Lost at SCLC: a review of potential platinum sensitizers16
Role of myeloid-derived suppressor cells in tumor recurrence16
Preface16
The role of bone marrow adipocytes in cancer progression: the impact of obesity16
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis16
The cure from within? a review of the microbiome and diet in melanoma16
The role of obesity and bariatric surgery-induced weight loss in breast cancer15
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions15
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors15
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?15
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer15
Biography—Mikhail Kolonin15
The role of the metabolite cargo of extracellular vesicles in tumor progression15
The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues15
Preface15
Biographies14
Epigenetic drugs in cancer therapy14
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine14
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment14
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance14
Nanotechnology-aided advancement in the combating of cancer metastasis14
Potential biomarkers for immunotherapy in non-small-cell lung cancer13
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics13
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin12
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies12
Epigenetic control of pancreatic cancer metastasis12
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives11
Correction to: Connecting the human microbiome and pancreatic cancer11
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response11
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings11
Insights into the role of senescence in tumor dormancy: mechanisms and applications11
The timing of adiposity and changes in the life course on the risk of cancer11
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response10
Natural compounds targeting nuclear receptors for effective cancer therapy10
Epigenetic markers and therapeutic targets for metastasis10
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance10
Recapitulating the potential contribution of protein S-palmitoylation in cancer10
Glioblastoma stem cell metabolism and immunity10
Preface10
What do cellular responses to acidity tell us about cancer?10
Advancements in gene therapies targeting mutant KRAS in cancers10
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases10
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies10
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance10
Oral delivery of RNAi for cancer therapy10
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead9
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance9
Obesity, cancer risk, and time-restricted eating9
Retraction Note: EET signaling in cancer9
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art9
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation9
Neuronal mimicry in tumors: lessons from neuroscience to tackle cancer9
Evolving strategies for addressing CAR T-cell toxicities9
The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas9
Regulation and targeting of SREBP-1 in hepatocellular carcinoma9
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma9
0.042596817016602